CLINICAL TRIALS
IN ONCOLYTIC VIRUS THERAPY
For GBM, HCC, HNSCC, pancreatic cancer, and TNBC, clinical trial enrollment is the only available access pathway to onco
analyticsAt a Glance
- check_circleOncolytic virus trials test genetically modified viruses that selectively infect and kill tumours
- check_circleCG0070, GL-ONC1, and IMLYGIC combinations with checkpoint inhibitors are in active trials
- check_circleTrials focus on melanoma, glioblastoma, bladder cancer, and head and neck cancers
- check_circleChina and the US lead in active oncolytic virus trial enrolment
For Most Cancers, the Trial Is the Treatment
For GBM, HCC, HNSCC, pancreatic cancer, and TNBC, the clinical trial is not a research option alongside standard care. It is the only available access pathway to oncolytic virus therapy.
βThree practical variables determine whether a specific trial is worth pursuing: whether the viral platform has meaningful clinical data for this cancer type, whether the trial is actively enrolling at an accessible site, and whether prior treatment history preserves eligibility.β
Key Active Trials by Cancer Type
| Cancer Type | Agent / Trial | Phase | Notes |
|---|---|---|---|
| Melanoma | T-VEC + pembrolizumab, nivolumab, or ipilimumab | Phase II/III | ClinicalTrials.gov: "talimogene" AND "melanoma", Open Studies |
| Glioblastoma (GBM) | PVSRIPO; DNX-2401 + pembrolizumab | Phase III; Phase II | PVSRIPO primarily at Duke; Phase III ongoing |
| Pediatric High-Grade Glioma | G207 (engineered HSV-1) | Phase II/III | Phase II showed responses in DIPG; most significant unmet need in the field |
| HCC / Solid Tumors | VG161 (multi-payload HSV) | Phase I/II | Carries IL-12, IL-15, anti-PD-1 fragments; expressed at tumour site |
| TNBC / Pancreatic | Pelareorep + paclitaxel + anti-PD-L1; pelareorep + gem/nab-pac | Phase II | Reovirus platform; combination with chemotherapy and immunotherapy |
| Bladder Cancer | CG0070 | Phase II/III | BCG-unresponsive non-muscle-invasive bladder cancer |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Find Oncolytic Virus Clinical Trials for Your Diagnosis?
CancerFax identifies currently enrolling oncolytic virus trials matched to your specific cancer type and prior treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.